financetom
Business
financetom
/
Business
/
Update: Teck, Anglo American Agree to Merger of Equals to Create Anglo Teck, a Global Critical Minerals Company;
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Teck, Anglo American Agree to Merger of Equals to Create Anglo Teck, a Global Critical Minerals Company;
Sep 9, 2025 9:28 AM

12:09 PM EDT, 09/09/2025 (MT Newswires) -- (Updates shares and adds detail)

Teck Resources (TECK-A.TO, TECK-B.TO, TECK) and Anglo American said Tuesday they will combine in what they termed a "merger of equals" to form Anglo Teck, a Vancouver-headquartered copper company.

The combined group will be a top-five global copper producer, with more than 70% exposure to copper, the companies said.

Its portfolio will include six producing copper assets, along with iron ore and zinc businesses, and development projects in established mining jurisdictions. The combined company will also keep exposure to its broader portfolio, including iron ore, zinc and crop nutrients

The companies expect the merger to generate about $800 million in annual pre-tax synergies by the end of the fourth year, with 80% realized within two years.

They also forecast $1.4 billion in average annual pre-tax EBITDA revenue synergies from 2030 to 2049, primarily through integration of the Collahuasi and Quebrada Blanca operations.

Under the agreement, Anglo American will issue 1.3301 shares for each Teck class A and class B share. Ahead of completion, Anglo American plans to pay a special dividend of $4.5 billion, or about $4.19 a share, to its shareholders.

On closing, Anglo American and Teck shareholders will own about 62.4% and 37.6% of Anglo Teck, respectively. Anglo American's Duncan Wanblad will serve as chief executive officer with Teck chief executive Jonathan Price as deputy CEO, John Heasley as chief financial officer, and Sheila Murray as chair.

The boards of both companies unanimously recommend the merger to shareholders.

Teck's Class B shares were last seen up $7.16, or 15%. to $55.66 on the Toronto Stock Exchange.

Price: 55.79, Change: +7.29, Percent Change: +15.03

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
German rail reports disruptions to France routes due to vandalism
German rail reports disruptions to France routes due to vandalism
Jul 26, 2024
BERLIN, July 26 (Reuters) - Germany's Deutsche Bahn warned of disruptions to its long-distance rail network on Friday and asked passengers to check their connection before travelling following attacks on rail infrastructure in France ahead of the Paris Olympic Games. Due to damage caused by vandalism, Deutsche Bahn's long-distance services between France and Germany are subject in the short term...
Karooooo Terminates Secondary Public Offering Due to Market Conditions
Karooooo Terminates Secondary Public Offering Due to Market Conditions
Jul 26, 2024
05:18 AM EDT, 07/26/2024 (MT Newswires) -- Karooooo ( KARO ) said Friday Chief Executive Isaias Jose Calisto has terminated the secondary public offering of ordinary shares, first announced on July 24. The company said despite strong investor interest and oversubscription, Calisto decided to halt the offering due to recent market changes affecting the share price. As a result of...
--Atlantic Union Bankshares Keeps Quarterly Dividend of $0.32 a Share, Payable Aug. 23 to Shareholders as of Aug. 9
--Atlantic Union Bankshares Keeps Quarterly Dividend of $0.32 a Share, Payable Aug. 23 to Shareholders as of Aug. 9
Jul 26, 2024
05:13 AM EDT, 07/26/2024 (MT Newswires) -- Price: 41.17, Change: -0.09, Percent Change: -0.22 ...
Calliditas Therapeutics Says Liver Disease Therapy Met Main Goal in Phase 2b Study
Calliditas Therapeutics Says Liver Disease Therapy Met Main Goal in Phase 2b Study
Jul 26, 2024
05:15 AM EDT, 07/26/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Friday a phase 2b study of its setanaxib experimental therapy to treat patients with primary biliary cholangitis and elevated liver stiffness met its primary goal. In the study, patients treated with setanaxib showed statistically significant improvement in Alkaline Phosphatase for both doses tested compared with placebo, the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved